Edwards Lifesciences Corp (NYSE:EW) VP Larry L. Wood sold 6,300 shares of the business’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $121.00, for a total value of $762,300.00. Following the completion of the transaction, the vice president now directly owns 116,148 shares in the company, valued at $14,053,908. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Larry L. Wood also recently made the following trade(s):

  • On Friday, December 15th, Larry L. Wood sold 18,960 shares of Edwards Lifesciences stock. The shares were sold at an average price of $114.58, for a total value of $2,172,436.80.
  • On Wednesday, November 15th, Larry L. Wood sold 18,960 shares of Edwards Lifesciences stock. The shares were sold at an average price of $104.76, for a total value of $1,986,249.60.

Edwards Lifesciences Corp (NYSE EW) opened at $123.91 on Friday. Edwards Lifesciences Corp has a 52 week low of $86.55 and a 52 week high of $124.10. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.76 and a current ratio of 3.49. The firm has a market capitalization of $25,758.38, a P/E ratio of 33.72, a P/E/G ratio of 1.95 and a beta of 0.51.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Tuesday, October 24th. The medical research company reported $0.84 earnings per share for the quarter, missing analysts’ consensus estimates of $0.86 by ($0.02). Edwards Lifesciences had a return on equity of 27.22% and a net margin of 22.47%. The firm had revenue of $821.50 million for the quarter, compared to analyst estimates of $833.85 million. During the same period last year, the company posted $0.68 earnings per share. The firm’s quarterly revenue was up 11.1% compared to the same quarter last year. analysts anticipate that Edwards Lifesciences Corp will post 3.76 earnings per share for the current year.

Edwards Lifesciences declared that its board has authorized a share repurchase program on Thursday, December 7th that permits the company to buyback $1.00 billion in outstanding shares. This buyback authorization permits the medical research company to repurchase shares of its stock through open market purchases. Shares buyback programs are generally an indication that the company’s board believes its shares are undervalued.

A number of research analysts have recently issued reports on the company. Barclays raised Edwards Lifesciences from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $125.00 to $135.00 in a research note on Thursday, January 4th. Evercore ISI assumed coverage on Edwards Lifesciences in a research note on Wednesday, January 3rd. They issued an “outperform” rating and a $140.00 price objective on the stock. JPMorgan Chase & Co. downgraded Edwards Lifesciences from an “overweight” rating to a “neutral” rating in a research note on Tuesday, January 2nd. Cowen set a $135.00 price objective on Edwards Lifesciences and gave the company a “buy” rating in a research note on Sunday, December 10th. Finally, BMO Capital Markets reissued a “buy” rating and issued a $137.00 price objective on shares of Edwards Lifesciences in a research note on Friday, December 8th. Six investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $129.57.

A number of hedge funds have recently bought and sold shares of the stock. Diversified Trust Co acquired a new position in Edwards Lifesciences during the 4th quarter worth approximately $209,000. State of Alaska Department of Revenue increased its holdings in Edwards Lifesciences by 376.8% during the 4th quarter. State of Alaska Department of Revenue now owns 24,625 shares of the medical research company’s stock worth $2,774,000 after purchasing an additional 19,460 shares in the last quarter. Syntal Capital Partners LLC bought a new stake in Edwards Lifesciences during the 4th quarter worth approximately $315,000. Schwab Charles Investment Management Inc. increased its holdings in Edwards Lifesciences by 4.1% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 723,832 shares of the medical research company’s stock worth $81,584,000 after purchasing an additional 28,821 shares in the last quarter. Finally, First National Trust Co increased its holdings in Edwards Lifesciences by 77.8% during the 4th quarter. First National Trust Co now owns 16,298 shares of the medical research company’s stock worth $1,837,000 after purchasing an additional 7,134 shares in the last quarter. 81.61% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This piece of content was published by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.watchlistnews.com/edwards-lifesciences-corp-ew-vp-larry-l-wood-sells-6300-shares/1815193.html.

About Edwards Lifesciences

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Insider Buying and Selling by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.